| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
TRANSLATIONAL AND CLINICAL RESEARCH |
aDepartment of Molecular Science & Applied Medicine (Gastroenterology & Hepatology), Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi, Japan;
bCenter of Regenerative Medicine and Cell Therapy, Yamaguchi University Hospital, Yamaguchi, Japan
Key Words. Liver cirrhosis • Regenerative medicine • Liver regeneration • Autologous bone marrow cell infusion • Stem cell therapy • Clinical trial
Correspondence: Shuji Terai, M.D., Ph.D., Department of Molecular Science & Applied Medicine (Gastroenterology & Hepatology), Yamaguchi University Graduate School of Medicine, Minami Kogushi 1-1-1, Ube, Yamaguchi 755-8505, Japan. Telephone: +81-836-22-2241; Fax: +81-836-22-2240; e-mail: terais{at}yamaguchi-u.ac.jp
Received November 4, 2005;
accepted for publication June 10, 2006.
First published online in STEM CELLS EXPRESS June 15, 2006.
We here report nine liver cirrhosis (LC) patients that underwent autologous bone marrow cell infusion (ABMI) from the peripheral vein. Subjects were patients with LC with total bilirubin of less than 3.0 mg/dl, platelet count of more than 5 (1010/l), and no viable hepatocellular carcinoma on diagnostic imaging. Autologous bone marrow (BM; 400 ml) was isolated from the ilium under general anesthesia. Mononuclear cells (MNCs) were separated by cell washing and were infused via the peripheral vein. MNC characteristics were confirmed by fluorescence-activated cell sorting analysis (CD34, CD45, and c-kit). After ABMI therapy, liver function was monitored by blood examination for 24 weeks. From 400 ml of BM, we obtained 7.81 ± 0.98 x 109 MNCs. After washing, 5.20 ± 0.63 x 109 MNCs were infused into patients with LC. Significant improvements in serum albumin levels and total protein were observed at 24 weeks after ABMI therapy (p < .05). Significantly improved Child-Pugh scores were seen at 4 and 24 weeks (p < .05). 
-Fetoprotein and proliferating cell nuclear antigen (PCNA) expression in liver biopsy tissue was significantly elevated after ABMI therapy (p < .05). No major adverse effects were noted. In conclusion, ABMI therapy should be considered as a novel treatment for patients with decompensated LC.
This article has been cited by other articles:
|
|
 |
|
  R. K. Burt, Y. Loh, W. Pearce, N. Beohar, W. G. Barr, R. Craig, Y. Wen, J. A. Rapp, and J. Kessler Clinical Applications of Blood-Derived and Marrow-Derived Stem Cells for Nonmalignant Diseases JAMA, February 27, 2008; 299(8): 925 - 936. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J Forbes Stem cell therapy for chronic liver disease choosing the right tools for the job Gut, February 1, 2008; 57(2): 153 - 155. [Full Text] [PDF]
|
|
|
|
 |
|
 K. Kubota, J. Soeda, R. Misawa, M. Mihara, S. Miwa, H. Ise, M. Takahashi, and S. Miyagawa Bone marrow-derived cells fuse with hepatic oval cells but are not involved in hepatic tumorigenesis in the choline-deficient ethionine-supplemented diet rat model Carcinogenesis, February 1, 2008; 29(2): 448 - 454. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. C. Lyra, M. B. P. Soares, R. R. dos Santos, and L. G. C. Lyra Bone marrow stem cells and liver disease Gut, November 1, 2007; 56(11): 1640 - 1640. [Full Text] [PDF]
|
|
|
|
|
|
Y N Kallis, M R Alison, and S J Forbes Authors' reply Gut, November 1, 2007; 56(11): 1640 - 1641. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Lorenzini and P. Andreone Stem Cell Therapy for Human Liver Cirrhosis: A Cautious Analysis of the Results Stem Cells, September 1, 2007; 25(9): 2383 - 2384. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y N Kallis, M R Alison, and S J Forbes Bone marrow stem cells and liver disease Gut, May 1, 2007; 56(5): 716 - 724. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| STEM CELLS | THE ONCOLOGIST | CME | ALPHAMED PRESS JOURNALS |
